Metoprolol vs Atenolol
Metoprolol (Lopressor, Toprol-XL) and atenolol (Tenormin) are both cardioselective beta-1 adrenergic blockers widely used for hypertension, angina, and heart failure. They are among the most commonly prescribed beta-blockers in the world and share a very similar mechanism. Yet important differences in clinical evidence, CNS penetration, and guideline support have made metoprolol succinate (the extended-release form) the generally preferred option in US cardiology practice.
Quick Comparison
| Feature | Metoprolol (Lopressor / Toprol-XL) | Atenolol (Tenormin) |
|---|---|---|
| Drug Class | Cardioselective beta-1 blocker | Cardioselective beta-1 blocker |
| Generic Name | Metoprolol tartrate (IR) / Metoprolol succinate (XL) | Atenolol |
| Brand Name | Lopressor (tartrate), Toprol-XL (succinate) | Tenormin |
| Approved For | Hypertension, angina, heart failure (succinate), post-MI, certain arrhythmias | Hypertension, angina, post-MI |
| Available as Generic | Yes | Yes |
| Key Advantage | MERIT-HF trial shows mortality benefit in heart failure; preferred by US guidelines; better CNS penetration may reduce arrhythmia risk | Once-daily dosing; does not cross blood-brain barrier as readily (fewer vivid dreams/CNS effects); renally eliminated (no hepatic concern) |
| Main Drawback | Hepatically metabolized (concern in liver disease); more CNS side effects (vivid dreams, fatigue) | Less robust evidence for heart failure mortality benefit; some guidelines suggest slightly inferior stroke prevention; twice-daily dosing for some formulations |
How They're Similar
Both metoprolol and atenolol are beta-1 selective blockers, meaning they preferentially block beta-1 adrenergic receptors in the heart over beta-2 receptors in the lungs and peripheral vasculature. This selectivity makes them safer than non-selective beta-blockers in patients with mild to moderate reactive airway disease, though neither is completely safe in severe asthma or COPD.
Both drugs reduce heart rate and blood pressure, and both are used for hypertension, stable angina, and post-myocardial infarction management. Both are generic, inexpensive, and widely available. Both carry the class-wide warnings about abrupt discontinuation — sudden stopping of beta-blockers can trigger rebound hypertension, angina, or even myocardial infarction in predisposed patients.
Key Differences
Heart failure evidence: This is the most clinically significant difference. Metoprolol succinate (Toprol-XL) was evaluated in the landmark MERIT-HF trial, which demonstrated a significant reduction in all-cause mortality in patients with chronic heart failure with reduced ejection fraction (HFrEF). This trial established metoprolol succinate as a guideline-directed medical therapy for heart failure. Atenolol lacks equivalent landmark trial evidence for heart failure mortality benefit and is generally not recommended in this setting by ACC/AHA guidelines.
CNS penetration: Metoprolol is more lipophilic than atenolol and crosses the blood-brain barrier more readily. This has practical implications: metoprolol causes more CNS side effects such as vivid dreams, sleep disturbances, and fatigue in some patients. Atenolol, being more hydrophilic and renally eliminated, crosses the blood-brain barrier less and may cause fewer CNS effects in susceptible individuals.
Metabolism and elimination: Metoprolol is hepatically metabolized via CYP2D6; patients who are CYP2D6 poor metabolizers can accumulate higher drug levels. Atenolol is primarily renally eliminated and requires dose adjustment in kidney impairment but is less affected by hepatic function. This makes each preferable in different comorbidity scenarios.
Stroke prevention: Some analyses and meta-analyses have suggested atenolol may be slightly inferior to other antihypertensives — including metoprolol — for stroke prevention in hypertension, though this remains somewhat debated.
Metoprolol: Strengths & Weaknesses
Strengths: Guideline-endorsed for heart failure with reduced EF (succinate formulation), strong evidence base across cardiovascular indications, once-daily extended-release formulation widely used. Preferred by most US cardiology guidelines.
Weaknesses: More CNS side effects (vivid dreams, fatigue, depression in some). Subject to CYP2D6 drug interactions. Requires dose adjustment in severe hepatic impairment.
Atenolol: Strengths & Weaknesses
Strengths: Fewer CNS side effects, renally eliminated (predictable kinetics in hepatic disease), once-daily dosing. Suitable for patients who experience CNS effects on metoprolol.
Weaknesses: Not preferred for heart failure (lacks mortality trial support), some guideline authorities rank it below metoprolol and other beta-blockers for stroke prevention. Requires dose adjustment in renal impairment.
Frequently Asked Questions
Can you switch from atenolol to metoprolol?
Yes, switching between cardioselective beta-blockers is generally straightforward and is commonly done, particularly when heart failure is diagnosed and guideline-directed therapy is being optimized. The transition is typically done under medical supervision to ensure blood pressure and heart rate remain stable.
Which causes more fatigue and vivid dreams?
Metoprolol, due to its higher lipophilicity and CNS penetration, is more commonly associated with fatigue, vivid dreams, and sleep disturbances. Patients who experience these effects on metoprolol sometimes do better on atenolol. However, fatigue is a class effect of beta-blockers and can occur with either drug.
Why is metoprolol preferred for heart failure over atenolol?
The MERIT-HF trial specifically demonstrated that metoprolol succinate reduced mortality in heart failure with reduced ejection fraction. Atenolol was not tested in an equivalent landmark trial for this indication, and clinical guidelines (ACC/AHA) specifically recommend carvedilol, metoprolol succinate, or bisoprolol for HFrEF — not atenolol.
Are beta-blockers safe in asthma?
Beta-blockers can worsen bronchospasm. Cardioselective agents like metoprolol and atenolol are relatively safer than non-selective beta-blockers in patients with mild asthma or COPD, but are still used with caution and are generally avoided in severe or uncontrolled asthma. Discuss this with your prescriber.
Related Pages
⚠ This comparison is for informational purposes only. Never start, stop, or switch medications without guidance from a licensed healthcare provider. Individual responses to medication vary significantly.